Research Flow Cytometry
Dmitrieva-Posocco OS, Dzutsev A, Posocco D, Yuan W, Thovarai V, Hou V, Mufazalov I, Gunzer M, Shilovskyi I, Khaitov M, Trinchieri G., Waisman A, Grivennikov SI. Cell-type specific responses to interleukin-1 control microbial invasion and tumor elicited inflammation in colorectal cancer. Immunity. 2019 Jan 15;50(1):166-180.e7. doi: 10.1016/j.immuni.2018.11.015.PMID:30650375, PMCID: PMC6490968.
Peshkova IO, Aghayev T, Fatkhullina AR, Makhov P, Titerina EK, Eguchi S, Tan YF, Kossenkov AV, Khoreva MV, Gankovskaya LV, Sykes SM, Koltsova EK. IL27R signaling is required for Angiotensin II-induced stress hematopoiesis to promote Abdominal Aortic Aneurysm. Nature Communications. 2019, Nov 6;10(1):5046. doi: 10.1038/s41467-019-13017-4. PMCID: PMC6834661.
Wang Y, Bernhardy AJ, Nacson J, Krais JJ, Tan YF, Nicolas N, Radke MR, Handorf E, Guevara AL, Balmaña J, Swisher EM, Serra V, Peri S and Johnson N. BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. Nature Communications. 2019. Dec 11;10(1):5661. doi: 10.1038/s41467-019-13530-6. PMC6906494.
Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T. 2018. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood 132:67-77. PMCID: PMC6034642.
Nacson J, Krais JJ, Bernhardy AJ, Clausen E, Feng W, Wang Y, Nicolas E, Cai KQ, Tricarico R, Hua X, DiMarcantonio D, Martinez E, Zong D, Handorf EA, Bellacosa A, Testa JR, Nussenzweig A, Gupta GP, Sykes SM, Johnson N. 2018. BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep. 24:3513-3527. PMC6219632.
Fahl, S.P., Coffey, F., Kain, L., Zarin, P., Teyton, L., Zúñiga-Pflücker, J.C., Kappes, D.J., and Wiest, D.L. 2018. Role of a selecting ligand in shaping the γδ TCR repertoire. PNAS 115:1889-1894. PMC5828614.
Fatkhullina AR, Peshkova I.O, Dzutsev A, Aghayev T, McCulloch J.A., Thovarai V., Badger J.H., Vats R., Sundd P., Tang H-Y, Kossenkov A.V., Hazen SL, Trinchieri, G, Grivennikov SI, Koltsova EK. 2018. An interleukin-23- interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis. Immunity 49:1-15. PMC6257980.
Zhou C, Martinez E, Di Marcantonio D, Solanki-Patel N, Aghayev T, Peri S, Ferraro F, Skorski T, Scholl C, Fröhling S, Balachandran S, Wiest DL, Sykes SM. JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia. Leukemia. 2017 May;31(5):1196-1205. PMCID: PMC5473421.
Liu, Y., Yuelling, L.W., Wang, Y., Du, F., Gordon, R.E., O'Brien, J., Ng, J.M.Y., Robins, S., Lee, E.H., Liu, H., Curran, T., Yang, Z.J. Astrocytes promote medulloblastoma progression through hedgehog secretion. Cancer Res. 77(23): 6692-6703, 2017. PMID: 28986380, PMC5759326.
Hayakawa K, Formica AM, Zhou, Y., Ichikawa, D., Asano, M., Li, Y.S., Shinton, S.A., Brill-Dashoff J., Nunez, G., Hardy, R.R. 2017. NLR Nod1 signaling promotes survival of BCR-engaged mature B cells through up-regulated Nod1 as a positive outcome. J. Exp. Med. 214: 3067-3083. PMID:28878001. PMCID: PMC5626402.
Human Immune Monitoring
MacFarlane 4th, A.W., Yeung, H.-M., Alpaugh, R.K., Dulaimi, E., Engstrom, P.F., Dasari, A., Campbell, K.S.*, and Vijayvergia, N.* (2021) Impacts of Pembrolizumab Therapy on T and NK cells in Patients with High-grade Neuroendocrine Neoplasms. Cancer Immunol. Immunother., 70:1893-1906. PMCID: 8195815. *Corresponding authors.
Barta, S.K., Zain, J., MacFarlane 4th, A.W., Smith, S.M., Ruan, J., Fung, H.C., Tan, C.R., Yang, Y., Alpaugh, R.K., Dulaimi, E., Ross, E.A., Campbell, K.S., Khan, N., Rawat, S., Fowler, N.H., Fisher, R.I., and Oki, Y. (2019) Phase II Study of the PD1-inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clin. Lymphoma Myeloma Leuk., 19:356-364. PMCID: 7433797.
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Jang HJ, Hostetter G, MacFarlane AW, Madaj Z, Ross EA, Hinoue T, Kulchycki JR, Burgos RS, Tafseer M, Alpaugh RK, Schwebel CL, Kokate R, Geynisman DM, Zibelman MR, Ghatalia P, Nichols PW, Chung W, Madzo J, Hahn NM, Quinn DI, Issa JJ, Topper MJ, Baylin SB, Shen H, Campbell KS, Jones PA, Plimack ER. Clin Cancer Res. 2023, 29:2052-2065. PMCID: PMC10233355
Zibelman, M., MacFarlane IV, A.W., Costello, K., McGowan, T., O’Neill, J., Kokate, R., Borghaei, H., Denlinger, C.S., Dotan, E., Geynisman, D.M., Jain, A., Martin, L., Obeid, E., Sherman, J., Devarajan, K., Ruth, K., Alpaugh, R.K., Dulaimi, E., Cukierman, E., Einarson, Campbell, K.S., and Plimack, E.R. A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors. Nature Communications, 2023, Nature Commun., 14:4513. PMCID: PMC10374608.